Pulmonary Embolism

 

Venous thromboembolism is a serious disease. Both deep vein thrombosis and pulmonary embolism frequently result in devastating impacts for patients in both the short and the long term. Pulmonary Embolism affects about 1000 out of every 1 million people with 200 of those cases considered to have an intermediate-high and high risk of mortality. Pulmonary Embolism, while preventable, is the 3rd leading cause of cardiovascular death.
 

As high mortality rates have shown little improvement over the last 20 years, it is clear acute PE patients need to be managed differently. We know that conservative treatment options, as recommended by the guidelines leave thrombus behind in 20-50% of the patients. Literature shows the mortality number on anticoagulation only is still high and the majority of venous clot is lytic-resistant by time of treatment. Thrombolysis comes with significant risk of bleeds.  
 

This section presents key papers, IHR and HR PE case reports and also interviews with the Key Opinion Leaders discussing on how new technologies, like a lytic-free thrombectomy, can transform the treatment of acute Pulmonary Embolism.

Close X
Other videos you might like

Section Advisor

Prof Felix Mahfoud

The Pulmonary Embolism section is supported by

Recent Videos

Video

Clinical Data

Thomas Tu, Jay Giri, Felix Mahfoud, et al

Watch time: 52m 30s

Video

Immediate Impact

Michael Piorkowski, Pablo Salinas, Gregor Leibundgut, et al

Watch time: 1h 4m 51s

Video

Patient Pathway

Maximilian de Bucourt, Ana Viana Tejedor, Ole Jørgen Grøtta, et al

Watch time: 57m 52s

Video

Patient Selection

Stefano Barco, Bernhard Gebauer, Catalin Toma, et al

Watch time: 57m 59s

Video

What are the European Updates on the FLASH Registry?

Felix Mahfoud,

Watch time: 5m

Video

Why Do You See a Need for Update the Current Risk Stratification for Acute

Sripal Bangalore,

Watch time: 9m 4s